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Summary
T-cell ALL (T-ALL) is an aggressive malignancy of T-cell
progenitors. Although survival outcomes in T-ALL have
greatly improved over the past 50 years, relapsed and refrac-
tory cases remain extremely challenging to treat and those
who cannot tolerate intensive treatment continue to have
poor outcomes. Furthermore, T-ALL has proven a more
challenging immunotherapeutic target than B-ALL. In this
review we explore our expanding knowledge of the basic
biology of T-ALL and how this is paving the way for repur-
posing established treatments and the development of novel
therapeutic approaches.
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The need for new therapies in T-ALL was once driven by the
inferior survival outcomes seen in T-ALL compared to B-
ALL. Improvements in chemotherapy usage with treatment
intensification and minimal residual disease (MRD) monitor-
ing have made a major impact on this disparity.1 The intro-
duction of treatment escalation based on MRD has meant
that despite a three-fold higher rate of positive MRD at end
of induction (EOI) in T-ALL versus B-ALL,2 both subtypes
now have equivalent survival outcomes in children.3 This is
particularly relevant to early T-cell precursor T-ALL (ETP-
ALL), historically associated with a very high-risk of treat-
ment failure,4 but now with excellent outcomes on MRD
risk-directed protocols.5-7 In adults, survival in T-ALL now
surpasses B-ALL on some protocols.8 Focus has also been
directed to appropriate de-escalation of treatment in those
with low risk MRD.9
Long term survival outcomes approach 50% in adults able
to tolerate intensive treatment and exceed 90% in childhood
ALL,9-12 a remarkable prognosis that may reflect the superior
tolerance of children to chemotherapy and a difference in
the genetics of childhood leukaemia.13,14 The vast majority of
children that remain in remission 2 years from diagnosis will
be cured, with rare cases of late relapse (>5 years) likely rep-
resenting a clonally unrelated secondary T-ALL.15 However
relapsed T-ALL is highly aggressive and often resistant to
glucocorticoids and chemotherapy, with survival of around
50% in children and less in adults, with the worst outcome
in those with the shortest duration of remission.16-19 For
those adults who relapse, allogeneic transplant offers the best
chance of cure, with recently reported survival outcomes of
40%.19 Despite modern treatment protocols, durable
responses for adults unable to proceed to transplant are unli-
kely, with a median survival of only 8 months.19 In children,
allogeneic bone marrow transplantation is generally reserved
for those with high-risk relapsed disease and remains one of
the few curative options for these patients.20
Genetic markers can identify good prognostic subgroups
with potential for treatment de-escalation. Patients with both
NOTCH1 and FBXW7 mutations, or two NOTCH1 muta-
tions, have been shown to have an excellent outcome, with
100% 5 years survival in this patient subgroup treated on the
paediatric UKALL2003 trial,21 and improved survival seen in
adults.22,23 However not all findings are as clear cut, for
example PTEN aberrations have added additional prognostic
value on some trials,24-26 but not others.27 Given the rarity
of the disease, most studies are underpowered to detect small
but meaningful differences in outcome among genetic sub-
groups. As an example, outcome analyses based solely on
NOTCH pathway mutations alone are confounded by the
high frequency of these mutations in TLX+ cases (approx.
90%) and relative rarity in ETP-ALL (approx. 20%).28
The poor outcomes seen in relapsed/refractory (R/R)
T-ALL highlight a pressing need for novel treatments.
Improved understanding of the genetics of both normal and
aberrant T-cell differentiation is offering new therapeutic
avenues. T-ALL is a genetically heterogeneous disease, which
can be sub-classified based on first-hit class-defining lesions
that commonly affect master regulatory transcription factors
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(e.g. TAL1, LMO1/2, TLX1/3, HOXA). Transcription factors
have proven extremely difficult to target pharmacologically,
thus the focus of drug development has been on second hit
mutations in key signalling pathways. Herein we review some
current areas of active translational research in this field.
Nelarabine
Nelarabine is the soluble prodrug of ara-G, which is selec-
tively cytotoxic to T leukaemic cells, likely due to their low
endogenous SAMHD1 levels.29 Initial early phase trials of
nelarabine showed its efficacy as a single agent in paediatric
relapsed/refractory T-ALL, with neurotoxicity the most com-
mon dose-limiting toxicity.30,31 In adults, an alternate day
dosing schedule limited neurotoxicity whilst maintaining an
over all response rate (ORR) of 31%.32 Subsequent data
showed the efficacy of Nelarabine in combination with
chemotherapy, with NEC (Nelarabine, Etoposide and
Cyclophosphamide), with an impressive complete remission
(CR) of 71% in relapsed patients.33
More recent data supporting the upfront use of Nelara-
bine in children and young adults has led some to consider
it as standard of care in paediatric T-ALL.34,35 Data for its
upfront use in adults is awaited from the UKALL14 trial.
NOTCH inhibitors
NOTCH receptors are part of a conserved protein family that
can act both as oncogenes or tumour suppressors, depending
on the cellular context.36 NOTCH1 is important for thymo-
cyte development, committing common lymphoid progeni-
tors to a T-cell fate. Activating mutations of NOTCH1 have
been found in almost two-thirds of paediatric and adult T-
ALL cases.37,38
As one of the most frequently mutated genes in T-ALL,
NOTCH1 has generated considerable interest as a therapeutic
target. Gamma secretase inhibitors (GSI), originally developed
for Alzheimer’s disease, act by preventing the cleavage and
activation of the intracellular NOTCH1 fragment (Fig 1A).
Their early promise has since been hampered by marked gas-
trointestinal (GI) toxicity.39 NOTCH1 is an important regula-
tor of intestinal goblet cells and NOTCH1 inhibition by GSIs
causes goblet cell accumulation via upregulation of the tran-
scription factor KLF4, resulting in significant diarrhoea
(Fig 1B).40 However, the use of a pulsed treatment schedule41
and the addition of glucocorticoids have reduced this toxic-
ity,42 with one reported case of a CR in a patient treated with a
GSI and dexamethasone.43 Not only do glucocorticoids
improve the side effect profile of GSIs, but also the two treat-
ments work synergistically to induce apoptosis of T-ALL cells,
possibly due to increased expression of the glucocorticoid
receptor NR3C1 in the presence of the combination.42 How-
ever, a recently reported phase 1 trial using a novel inhibitor
of the NOTCH ICD in combination with dexamethasone con-
tinued to show dose limiting GI toxicity and limited clinical
efficacy.44 A more recent approach targeting PSEN1 aims to
reduce the systemic toxicity associated with GSIs.45 This sub-
unit of the gamma-secretase complex is more highly expressed
in leukaemic cells than normal developing T cells and its inhi-
bition has been well tolerated in animal studies.
The NOTCH transcriptional co-activator MAML1 is also a
potential target. Stapled a-helical peptides derived from
MAML1 (SAHM) compete with MAML1 and inhibit
NOTCH1-driven transcription. Mice treated with SAHM show
a decrease in leukaemic cell burden and corresponding reduc-
tion in NOTCH1 target gene expression, including MYC.46
Additionally their side effect profile seems tolerable in animal
models, without the GI toxicity associated with GSIs.
Another method of modulating NOTCH involves the use
of the proteasome inhibitor bortezomib, a standard of care
treatment in myeloma. Bortezomib has activity in relapsed/
refractory T-ALL, potentially by inhibiting transcriptional
expression of NOTCH1.47 In a small cohort of children with
relapsed/refractory ALL, bortezomib appeared to have partic-
ular efficacy in T-ALL with complete response rates of over
70% when used in conjunction with chemotherapy.48
There are other considerations that have clinical relevance
for NOTCH inhibition. Firstly, NOTCH1 mutations are often
late secondary subclonal events,14,49 meaning NOTCH inhibi-
tors are highly likely to select for NOTCH1 wild-type cells.
Secondly, resistance mechanisms can emerge whereby cells
are able to maintain MYC levels in the absence of NOTCH
signalling, for example through loss of FBXW7 or use of an
alternative MYC enhancer.50,51 In the former study, enhancer
usage switches from the NOTCH-MYC enhancer to a BRD4
regulated MYC enhancer, providing a rationale for combin-
ing NOTCH and BRD4 inhibitors.50
PI3K inhibitors
The PI3K-mTOR pathway plays a key role in both normal
T cell and malignant cell development. Phosphoinositide 3
kinases (PI3K) are a family of lipid kinases that act as sec-
ond messengers and are broadly divided into three classes,
which share a common core PI3K motif (Fig 2). Almost
half of T-ALL cases have aberrant PI3K activation occur-
ring through deletion or mutation or PTEN, activating
mutations of PIK3R1 (typically N564D), PIK3CD (typically
E1021K), or loss of function mutations of USP7.28 These
mutations are particularly enriched in the TAL1
subgroup,28 with these two oncogenic pathways shown to
synergise in mouse models, possibly related to the ability
of AKT to phosphorylate and modulate TAL1 activity.52
This raises the possibility that the TAL1 subgroup could
be particularly susceptible to PI3K pathway modulation,
although this awaits further study.
Mutations in the PI3K pathway also correlate with response
to chemotherapy; homozygous deletions of PTEN appear to
confer a higher risk of early treatment failure53 and mutations
in PTEN are associated with primary glucocorticoid
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resistance.54 This is likely driven by AKT1-mediated phospho-
rylation of the glucocorticoid receptor, leading to impaired
nuclear localisation; T-ALL mouse models treated with gluco-
corticoids and an AKT inhibitor, showed an augmented anti-
leukaemic response, compared to mice treated with either
agent alone.55 Another synergistic approach looked to target
both PI3K and NOTCH when it was found that T-ALL cells
evade cell death when treated with PI3K/mTOR inhibition by
upregulating NOTCH target genes such as MYC.56
The mTOR inhibitor everolimus acts downstream of AKT
and in addition to chemotherapy, gave a 50% response rate
in a small cohort of heavily pre-treated R/R T-ALL patients57




Fig 1. (A) NOTCH is activated by three cleavage steps. In the golgi, NOTCH1 is first cleaved in the Heterodimerization (HD) domain by a
furin-like convertase (S1 cleavage) and held together by a non-covalent bond. On activation by ligand, the Lin-12/NOTCH repeats (LNR) domain
is pulled from the Heterodimerization (HD), exposing the S2 cleavage site to proteolytic cleavage by TNFa-converting enzyme (TACE). This trig-
gers S3 cleavage by the c-secretase complex in the transmembrane domain releasing ICN to translocate to the nucleus to bind CSL and the tran-
scriptional coactivator MAML activating a multitude of target genes, some of which are shown. (B) NOTCH1 determines intestinal cell fate.
NOTCH1 inhibition results in accumulation of mucin-producing goblet cells through a KLF4 dependent pathway, resulting in severe diarrhoea.40
[Colour figure can be viewed at wileyonlinelibrary.com]
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During normal lymphopoiesis, lymphocytes with hyperac-
tive responses undergo negative selection through over-acti-
vation of PI3K signalling.58,59 Thus, one concept gaining
traction is that TCR stimulation, such as through an activat-
ing CD3-targeting monoclonal antibody, rather than inhibi-
tion of PI3K signalling may be an exploitable route towards
initiating apoptosis in ALL cells.60 A potential concern of this
approach would be cytokine release syndrome, as occurred
previously in solid organ transplant studies using OKT3.61
IL7R-JAK-STAT inhibition
The IL7R-JAK-STAT pathway is responsible for transducing
cytokine signalling in the thymus and is required for normal
T-cell development. This pathway is frequently aberrantly
activated in the TLX1/3+ T-ALL subgroup, but very rarely in
TAL1+ T-ALL. Activating mutations occur at multiple levels
in the pathway, with recurrent mutations described in
STAT5B, IL7R, JAK1 and JAK3.62-66 Interestingly, JAK1
mutations appear to be more common in adult than paedi-
atric T-ALL, and have been associated with reduced overall
survival and a high relapse rate.67 Mice transplanted with
progenitor cells harbouring the most commonly identified
JAK3 mutation (M511I) develop an immature T-ALL
through activating JAK1.68
The majority of activating IL7R mutations described thus
far in T-ALL involve the insertion of a cysteine in the trans-
membrane domain leading to disulphide bonding and
ligand-independent IL7R homodimerization and JAK1 phos-
phorylation (Fig 3).62,64,67 Inhibition of the IL7R-JAK-STAT
pathway has shown efficacy using clinically available JAK
inhibitors in preclinical models69,70 and phase I/II clinical tri-
als of Ruxolitinib are planned. The disulphide bond and
homodimer can also be disrupted by the reducing agent N-
acetylcysteine (NAC) at doses readily achievable in patients.71
Given its affordability and widespread use in treating patients
with paracetamol overdose, such an approach would be par-
ticularly attractive in healthcare systems where targeted
agents are considered prohibitively expensive.
An additional aspect of JAK inhibition is the possibility of
restoring glucocorticoid sensitivity.72,73 This approach is par-
ticularly intriguing in ETP-ALL, since ETP-ALL tends to be
less sensitive to steroids than other T-ALL subtypes and
STAT5 is commonly activated even in the absence of clearly
identified upstream mutations.69,74
The long-term efficacy of JAK inhibition in T-ALL is
unclear. Treatment does not eradicate leukaemic cells
in vitro, leading to rapid relapse upon drug withdrawal, and
combination therapy is likely to be required.72 Moreover,
due to the specific site of JAK inhibitor binding, it is possible
that T-ALL cells will acquire resistance mutations, for exam-
ple in the ATP-binding pocket of the kinase domain, or with
mutations activating other JAK family members.75 Most clin-
ical JAK inhibitors act to competitively inhibit the ATP-bind-
ing pocket of the active JAK2 (Type 1), however there is
growing interest in Type 2 JAK inhibitors which bind the
ATP pocket of the inactive JAK, as well as a less-conserved
nearby allosteric pocket.76 This approach may provide a
route to avoid resistance. Another strategy is to target further
downstream of the IL7R-JAK pathway, such as the kinase
PIM1. PIM1 appears to be upregulated in response to
chemotherapy and steroids in a (CD127+)77 subset of T-ALL
Fig 2. The PI3K signalling pathway: PI3K is activated by several growth factor receptor tyrosine kinases or G protein-coupled receptors. Once
activated PI3K catalyses the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) to generate phosphatidylinositol 3,4,5-trisphos-
phate (PIP3). This activates the serine/threonine kinase AKT, which then drives mTOR to promote cell proliferation and survival. Dashed line
indicates the negative feedback loop involving mTORC1 and PI3K. The ubiquitin specific peptidase USP7 acts to stabilise PTEN, a negative regu-
lator of the PI3K pathway.
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cells and PIM1 inhibition may be an alternative or adjunct
to JAK inhibition. Such inhibitors are already in clinical trials
for myelofibrosis.
Targeting anti-apoptotic machinery
B Cell lymphoma 2 (BCL2) is an anti-apoptotic protein that
was first discovered from cloning the t(14;18) translocation
in a case of B cell lymphoma. BCL2 forms part of a protein
family that share the BCL2 homology (BH) domain. BH3
proteins, such as BAX and BAK, are pro-apoptotic proteins
that are sequestered by BCL2, BCL-XL and MCL1.78 More
mature T-ALL cell lines have been shown to be dependent
on BCL-XL, whereas ETP-ALL cells show a greater depen-
dency on BCL2 (Fig 4).79,80 Accordingly, ETP-ALL models
have shown particular sensitivity to Venetoclax over Navito-
clax, with reversal of this pattern in more mature T-ALL
cells.79 There is considerable clinical experience with Veneto-
clax in the treatment of CLL and more recently in AML,
where the drug is generally well-tolerated. There is accumu-
lating evidence for its use in T-ALL; a recent retrospective
report of the use of Venetoclax with chemotherapy in R/R
T-ALL showed that 6/13 patients achieved a morphological
remission.81 We suggest that Venetoclax should be a priority
for incorporation in upcoming clinical trials, for instance in
patients with high risk MRD at end of induction, or those
with relapsed/refractory disease.
Navitoclax binds preferentially to BCL-XL, with less
potent activity against BCL-2.82 Its initial promise in CLL
was limited by thrombocytopaenia,83 as platelet survival
requires normal function of BCL-XL. Despite this, it war-
rants testing in relapsed/refractory cortical and post-cortical
T-ALL, where intrinsic mitochondrial chemoresistance is
often the major barrier to achieving remission, although
thrombocytopenia will need to be cautiously managed.
Recent early phase trials of combination Venetoclax and
Navitoclax are promising: In a small, heavily pre-treated
patient cohort 50% of the T-ALL patients achieved CR/CRi
(EHA 2020 S116). MCL1 is also an important target, since
it has been associated with steroid resistance and poor out-
come in T-ALL, directly upregulated by a recently discov-
ered T-ALL oncogene called JDP2.84 Direct MCL1 inhibitors
such as S63845 have shown pre-clinical efficacy in T-ALL
and are in early phase trials.85 Alternative strategies that
downregulate MCL1 expression, such as the CDK9 inhibitor
AZD4573, also offer exciting new therapeutic opportunities
across diverse haematological cancers.86
Several mechanisms of acquired resistance to Venetoclax
have been described, including mutations of the drug bind-
ing site, deletions/mutations of BIM/BAX, and upregulation
of BCL-XL and MCL1.87 There is thus considerable interest
in using Venetoclax in combination with Navitoclax, or
MCL1 inhibitors, though how such combinations will be tol-
erated in terms of toxicity will need to be carefully assessed.
Fig 3. Schematic of anti-apoptotic dependencies in T-ALL according to level of differentiation arrest. ETP-ALL arrested early in T-cell develop-
ment are highly dependent on BCL2, with increasing dependency on BCL-XL in T-ALLs that arrest Adapted from Chonghaile et al. (reference
79) in the cortical/post-cortical stages. This corresponds to vulnerability to Venetoclax and Navitoclax respectively. ETP – early T-cell progenitor;
ISP immature single progenitor; EDP early double positive; DP double positive; SP single positive T-cell.
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Tyrosine kinase inhibitors
Aberrant tyrosine kinase activation in T-ALL occurs when
chromosomal translocations involving the ABL1 oncogene
result in ligand independent activation of the ABL1 kinase.88
However, unlike chronic myeloid leukaemia (CML), the
Philadelphia chromosome has only occasionally been
reported in T-ALL. Instead the ABL1 oncogene is fused with
other partners, typically NUP214 leading to constitutively
active kinases.89 These fusion products are still amenable to
inhibition with tyrosine kinase inhibitors (TKIs), a class of
drug that has transformed the outcomes of CML and
Ph+ALL. NUP214-ABL1 T-ALL cells, found in the TLX1/3
subgroups, respond to treatment with Imatinib, Nilotinib
and Dasatinib.90 These results have been recapitulated in vivo
in a NUP214-ABL1 T-ALL xenograft when imatinib treat-
ment resulted in a reduction of leukaemic cell burden, where
the addition of Venetoclax further improved the response.91
Whilst ABL translocations only account for approximately
5% of T-ALL cases, functional drug testing has unexpectedly
revealed that up to 30% of T-ALL cases are susceptible to
the ABL/SRC family kinase inhibitor Dasatinib.92 No correla-
tion was noted between responsiveness and established
genetic lesions, including ABL translocations, leading the
authors to propose that Dasatinib was targeting SRC, rather
than ABL. This hypothesis was consistent with the lack of
activity shown by other canonical ABL family kinase inhibi-
tors, such as Imatinib, that do not affect SRC signalling. The
in vitro activity of Dasatinib was confirmed by in vivo testing
and supported by case reports of T-ALL responders to Dasa-
tinib.93 These findings are strengthened by those of another
group who used in silico drug screening to identify up-regu-
lation of the SRC family kinase LCK as a possible therapeutic
target in T-ALL and demonstrated preclinical efficacy of
Dasatinib.94 Recently published data suggests synergy
between Dasatinib and dexamethasone mediated via LCK.95
Overall, it is likely that TKIs will have significant clinical
activity in T-ALL, but their clinical use will remain limited
until the identification of validated biomarkers.
Cyclin dependent kinase inhibitors
Cyclin dependent kinases (CDKs) are a large family of
kinases with diverse roles, including acting as transcriptional
co-factors and controlling cell cycle progression. Clinically
meaningful inhibition of CDKs has proved technically chal-
lenging due to their integral role in normal cell survival and
difficulties in targeting specific kinase isoforms. However, a
Fig 4. Schematic of anti-apoptotic dependencies in T-ALL according to level of differentiation arrest. ETP-ALL arrested early in T-cell develop-
ment are highly dependent on BCL2, with increasing dependency on BCL-XL in T-ALLs that arrest Adapted from Chonghaile et. al. (reference
79) in the cortical/post-cortical stages. This corresponds to vulnerability to Venetoclax and Navitoclax respectively. ETP – early T-cell progenitor;
ISP immature single progenitor; EDP early double positive; DP double positive; SP single positive T-cell.
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series of more specific small molecule inhibitors have recently
emerged.
D cyclins are key cell cycle regulators that bind and activate
CDK4 and 6, leading to activation of the E2F transcription fac-
tors that facilitate cell-cycle progression. Cyclin D3 is dysregu-
lated in T-ALL and has been shown to be integral to NOTCH
driven leukaemogenesis;28 mice lacking cyclin D3 are resistant
to NOTCH-driven transformation to T-ALL.96 Furthermore,
in a mouse model of T-ALL driven by activating mutations of
NOTCH1, conditional ablation of cyclin D3 resulted in
marked disease regression, findings that were phenocopied by
exposure to the Cyclin D-CDK4/6 kinase inhibitor.97 Efficacy
of CDK4/6 inhibition has also been demonstrated in NOTCH1
wildtype T-ALL cell lines where an in vivo model showed syn-
ergism with steroids and mTOR inhibitors.98 Several CDK4/6
inhibitors are now in clinical trials and the challenge remains
to identify targetable interdependencies between specific CDK
isoforms and different mutational drivers in order to synergise
their anti-leukaemic properties. In this regard, it will be impor-
tant to assess whether the recently discovered recurrent muta-
tions of CCND3 are a biomarker for sensitivity to CDK4/6
inhibition.28
CDK7 is a key constituent of the cyclin-activating kinase
(CAK) complex, which acts to modulate the cell cycle by
interacting with the general transcription factor, TFIIH. The
CAK complex promotes transcription by activating RNA
polymerase II (RNAPII) via CDK7-dependent phosphoryla-
tion. The novel agent THZ1 can specifically and irreversibly
inhibit CDK7 by covalently binding to an amino acid located
outside its kinase domain,99 resulting in cell death in T-ALL
cell lines (Fig 5). Interestingly, the activity of this agent may
be associated with its preferential inhibition of super-en-
hancer driven oncogenes, such as the non-coding mutations
that drive TAL1, providing a potential in vivo therapeutic
window.99,100
CDK9 regulates transcriptional elongation and is of inter-
est as an anti-cancer target in a range of malignancies, partic-
ularly those dependent on MCL1 (Fig 5). Targeted inhibition
had initially been challenging due to homology of its ATP-
binding site with other CDKs, until the development of the
specific inhibitor AZD4573.86 An alternative PROteolysis
Targeting Chimeras (PROTAC) approach was recently devel-
oped where THAL-SNS-032 targeted CDK9 protein for pro-
teosomal degradation, inducing apoptosis in T-ALL cell lines
in vitro.101
Drugs in development
In this section we briefly explore further potential therapies
that may emerge from encouraging preclinical data.
The Hedgehog pathway is an evolutionarily conserved sig-
nalling cascade, however its aberrant activation also drives
tumour growth and chemoresistance. This pathway is acti-
vated in up to a fifth of T-ALL and is associated with induc-
tion of chemotherapy resistance.102 Inhibition of GLI1, a
Hedgehog pathway transcription factor, resulted in improved
survival in T-ALL PDX models and could offer a novel target
for high-risk T-ALL.103
Fig 5. CDK7 and CDK9 regulate oncogenes and are therapeutic targets in T-ALL. Green box: super-enhancers driving oncogenes can be desta-
bilised by inhibition of chromatin interacting proteins such as BRD4. Yellow box: The initiation of RNA polymerase II (RNApolII) mediated
oncogene transcription is facilitated by phosphorylation of the C terminal tail on serine 5 and 7 by CDK7 as part of the TFIIH complex, which
occurs both at enhancers and gene start sites. CDK7 can be inhibited by small molecules such as THZ1. Red box: Transcriptional elongation by
RNApolII is facilitated by phosphorylation of RNApolII on serine 2 by CDK9 as part of the PTEFb complex. CDK9 can be targeted for degrada-
tion by the novel agent THAL-SNS-032 or inhibited by CDK9 inhibitors such as AZD4573. CDK9 inhibition has been associated with marked
downregulation of MCL1 expression.
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Histone deacetylases (HDAC) play a role in the regulation
of chromatin structure and the HDAC inhibitors (HDACi)
Panobinostat, Vorinostat and Romidepsin are already in clin-
ical use in myeloma and lymphoma. The broad-acting
HDACi panobinostat shows particular efficacy in vivo T-ALL
models with improved survival seen in combination with
chemotherapy.104 Interestingly, there is a suggestion that the
efficacy of panobinostat over other HDACi relates to its epi-
genetic inhibition of the oncogene MYC.105
Exportin 1 (XPO1) (also known as CRM1) is a nuclear-
cytoplasmic exporter protein involved in the transport of
several proteins involved in cell cycle regulation. It is the
only transporter of key tumour suppressors including TP53
and is upregulated in several malignancies, including T-ALL.
Selinexor, a selective inhibitor of nuclear export (SINE)
compound, is a small molecule XPO1 antagonist and is
FDA-approved for myeloma. It has shown preclinical efficacy
in T-ALL, although toxicity reported from clinical trials may
prove problematic.106
Heat shock proteins act as molecular chaperones for a
variety of proteins with key roles in oncogenesis, including
the JAK pathway and another, closely related kinase pathway,
TYK2. TYK2 acts to upregulate BCL2 via STAT1107 and its
inhibition by the drug Luminespib/AUY922 triggers apopto-
sis in T-ALL in vitro. It appears that this effect is mediated
via a reduction in TYK2 and subsequent downregulation of
BCL2.108 Early clinical trials of Luminespib in a range of
malignancies have been undertaken and this could yet be an
additional therapy in T-ALL.
Approximately 75% of proteins currently have no tar-
getable domain. PROteolysis Targeting Chimeras (PROTACs)
circumvents this problem by degrading proteins instead of
inhibiting them, thus broadening the number of potential
targets. This approach may be particularly relevant to dis-
eases such as T-ALL where the majority of driver transloca-
tions involve oncogenic transcription factors.
Another technique looks to change the method of drug
delivery, using nanoparticles, enabling optimized drug dosing
and potentially combining chemotherapy with a targeted
ligand. This remains a broadly experimental area of leukaemic
treatment, however the success of CPX-351 (a liposomal for-
mulation of cytarabine and daunorubicin) in AML demon-
strates the potential of this expanding therapeutic area.
Immunotherapy
Immunotherapies are a group of therapeutics that harness
the immune system to specifically attack malignant cells.
Broadly they can be divided into treatments that: (i) amplify
a natural anti-tumour immune response (e.g. immune check-
point blockade); or (ii) synthetic immunotherapies (e.g.
monoclonal antibodies or chimeric antigen receptor T or NK
cells). There have been limited studies of immune checkpoint
blockade in ALL and the relatively low mutational burden
seen, particularly in paediatric ALL may limit the expression
of tumour specific neo-antigens, on which this strategy is
thought to rely. By contrast, synthetic immunotherapies are
having a major impact in the treatment of B-ALL with recent
clinical advances including the use of Rituximab, Ino-
tuzumab, Blinatumomab and durable responses to anti-
CD19 chimeric antigen receptor (CAR)-T cell therapy.109
All of these successful synthetic immunotherapies rely on
the presence of an antigen that is strongly expressed on all
leukaemic blasts, but with limited expression on normal tis-
sues. In the case of B cells, strong expression of specific B cell
markers such as CD19, CD20 and CD22 have provided good
immune targets. Furthermore, whilst normal B cells are also
attacked, B cell aplasia is clinically manageable and therefore
precision targeting of leukaemic B cells is not an absolute
requirement. By contrast, immunotargeting T-ALL has a
number of technical hurdles Fig 6. Firstly, antigen expression
is variable at different stages of T cell differentiation, and
thus there is not a single antigenic target that is likely to be
applicable to all T cell malignancies. Secondly, immune
destruction of normal T cells would result in a life-threaten-
ing immune deficiency disorder. Thirdly, harvesting of autol-
ogous T cells for CAR T cell generation risks contamination
by T-ALL blasts. Lastly, CAR T cells expressing the same
antigen they are targeting would lead to fratricide and T-cell
exhaustion. There is therefore limited clinical experience of
synthetic immunotherapies in T-ALL, but a number of
promising approaches are emerging.
Monoclonal antibodies
One of the most promising candidates in the short term is the
anti-CD30 drug immunoconjugate Brentuximab Vedotin,
which is licensed for use in classical Hodgkin lymphoma and
anaplastic large cell lymphoma. Preclinical studies have shown
that CD30 is expressed in 13/34 of T-ALL cases tested by flow
cytometry, but pre-clinical evidence for functional efficacy is
lacking.110 As some T-ALL cases, typically of the ETP sub-
group, express CD33, there is also the potential to use Gem-
tuzumab Ozogamicin in such cases, but clinical data for this
approach in T-ALL has not been reported. Another potential
surface target in T-ALL is the activation marker CD38, which
is highly expressed on T-ALL blasts and targetable by the
monoclonal antibody daratumumab. Pre-clinical efficacy of
Daratumumab in T-ALL has translated into clinical responses
in four post-allogeneic relapsed/refractory cases who achieved
MRD negativity, an encouraging set of results for such aggres-
sive disease111-113 and the Delphinus phase II clinical trial is
currently recruiting in the UK (NCT03384654).
The early lymphoid cytokine receptor and T-ALL onco-
gene IL7R is a potentially attractive immunotherapy target.
Recent work has preclinically explored a novel human mono-
clonal antibody targeting IL7R, showing evidence that bind-
ing inhibits signalling, functionally sensitises cells to
glucocorticoids and elicits natural killer (NK) cell mediated
cellular cytotoxicity in vitro, and potentially in vivo.
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Furthermore, the antibody is internalised on binding, giving
a potential utility in chemo-immunotherapy.114 Whilst pro-
viding a platform for a number of promising approaches, the
potential for on- and off-target toxicities remain to be seen.
Chimeric antigen receptor cells
A number of CAR T or NK cell approaches have shown ben-
efit in pre-clinical studies, but there is no single antigenic
target that is expressed in all T-ALL cases. An anti-CD4 CAR
T cell has shown activity against a CD4+ T-ALL cell line in a
xenograft model and this approach circumvents CAR T cell
fratricide by sparing cytotoxic CD8+ effector cells.115 How-
ever, only a minority of T-ALL cases express CD4 and pro-
longed CD4 aplasia is likely to lead to life-threatening
infection.
An anti-CD3 CAR-NK cell line has shown activity against
a T-ALL cell line in a xenograft model.116 The use of a CD3
(A)
(B)
Fig 6. Potential immunotherapy approaches for T-ALL. (A) T-ALL specific neo-epitopes can be targeted by monoclonal antibodies (with or with-
out conjugated cytotoxic payloads) or used to target cellular cytotoxicity via T cell engagers (e.g. bi-specific T cell engagers (BiTE) or dual affinity
retargeting (DART)) or chimeric antigen T cells (CAR T); (B) targeting TRBC1 on TRBC1-expressing monoclonal T-ALL overcomes CAR T frat-
ricide and T cell immunodeficiency by affording the retention of a polyclonal T cell repertoire of TRBC2-expressing normal and CAR T cells.
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negative NK effector cell avoids any problem with CAR frat-
ricide. However, surface CD3 is a relatively mature T cell
marker that would not be expressed in all T-ALL cases and
this approach would again result in fatal T cell aplasia, albeit
depending on the persistence of NK activity. Similarly an
anti-CD5 CAR NK cell has been reported to show activity in
a xenograft model.117
Intriguing results have been presented from an anti-CD5
CAR T cell.118 CD5 is expressed on most normal T cells and
IgM secreting innate B1 B cells. In response to the anti-CD5
CAR T cell both normal and malignant T cells down-regulate
CD5, but normal T cells additionally up-regulate anti-apop-
totic proteins including BCL2 and PI-9 protecting themselves
from cell death. The result is ongoing anti-tumour activity,
with minimal CAR T fratricide. Importantly, these results
show that CAR T efficacy is not just limited to choice of
antigenic target, but also the susceptibility of the target cells
to the effector mechanisms of the CAR T cells. A potential
problem with this approach, however, is that chronic expo-
sure to the CD5 antigen may result in CAR T exhaustion.
Recent positive pre-clinical results have been achieved tar-
geting the CD1a antigen expressed in cortical T-ALL.119
However, CD1a+ T-ALL has a good prognosis, meaning
relapsed/refractory CD1a+ T-ALL is rare.120
One approach to avoid CAR T cell fratricide is to delete
the targeted antigen in the CAR T cells during CAR T cell
production. This has been successfully achieved in an anti-
CD7 CAR T cell that has its own CD7 loci disrupted by
CRISPR/Cas9 genome editing.121 Importantly, these CAR T
cells demonstrated both effective anti-tumour responses, but
also the ability to respond to viral peptides indicating that
some broader cellular immunity may be re-established from
the CAR T population itself. Another recently reported
strategy targeting CD7 involves a CD7 expression blocker
which results in the intracellular retention of CD7. Eight
patients treated with this approach had limited cytokine
release syndrome (CRS) (including no reported neurotoxic-
ity) and 50% remain cytokine release syndrome (CRS) MRD
negative (Zhang M et al, ASH 05/12/20).
An elegant approach has sought to exploit the mutual exclu-
sive expression of TRBC1 and TRBC2 at the TCRb b-constant
region, a process with similarities to B cell kappa/lambda
restriction.122 TRBC1 and TRBC2 differ by just four amino
acids. Normal T cells express one or other, but not both, while
clonal disorders such as T-ALL will express only one of the
antigens Fig 6. Generating a CAR T cell against TRBC1 cir-
cumvents both CAR T cell fratricide and T cell aplasia (killing
only 50% of polyclonal T-cells), while showing activity against
TRBC1+ T-ALL cell lines in a xenograft model. Early phase
clinical trials of this CAR T cell in T cell lymphoma are cur-
rently recruiting. It should be noted that high-risk ETP-ALL
cases that have arrested prior to TCRb rearrangement will not
express either isoform, with only approximately 25% of T-ALL
cases amenable to TRBC1 directed therapy.122
Considerations in multiply relapsed and
refractory patients ineligible for clinical trials
If possible, all relapsed/refractory patients should be entered
onto clinical trials (Table I). For refractory patients fit for
intensive therapy, our standard practice has been to attempt
re-induction with either Fludarabine-Cytarabine-Idarubicin
(FLA-Ida) or a Nelarabine containing regimen. However, for
patients ineligible for clinical trials who are fit for active treat-
ment, we would recommend considering the following possi-
bilities, although this assumes the ability to access the various
Table II. Potential drug treatments for consideration in relapsed/refractory T-ALL.
Drug Adjuvant treatment Appropriate patient cohort
Nelarabine Can be used as single agent
Combination with etoposide &
cyclophosphamide (NEC protocol)





Azacytidine/decitabine in combination with venetoclax
Non-ETP-ALL
Monitor for thrombocytopenia
Bortezomib Vincristine/steroids/daunorubicin/asparaginase Caution in patients with neuropathy
Patients fit for re-induction
FLT3 inhibitor Can be used as single agent FLT3 mutated (approx. 5% T-ALL)
Associated with ETP-ALL and CD117+
Ruxolitinib (or
other JAKi)
Dexamethasone (pre-clinical data suggesting synergy) IL7R or JAK activating mutations
Dasatinib Either as single agent or with chemotherapy combination No current validated biomarkers for patient selection.
LCK phosphorylation or in vitro drug
sensitivity testing may be of value
Daratumumab Vincristine/steroids/daunorubicin/asparaginase Appropriate antigen expression.
Clinical use currently unproven for brentuximab
and gemtuzumab
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agents on compassionate access schemes or through local/per-
sonal funding streams, accepting use of many of these agents is
outside licence, and usage should be assessed by a specialist
team on a case-by-case basis (Table II). Genetic and drug pro-
filing is likely to assist the best treatment approach.
Conclusion
Instigating novel therapies for T-ALL is challenging due to the
rarity of the disease, genetic heterogeneity and the toxicity
associated with ablating the T cell repertoire. Immunotherapy
has an increasing role in haematological cancers, with CAR T
cell trials beginning in T-lineage malignancies. However, CAR
T therapy requires expensive infrastructural support, both in
terms of production and delivery, and is unlikely to be avail-
able outside of select institutes in high-income countries.
Advances in our understanding of the genetics and epigenetics
of this disease have contributed to the novel uses of previously
well-described therapies, as well as the advent of new drugs.
Targeting synthetic lethal pathways, such as recently described
for CHK1 inhibition in EZH2 deficient T-ALL, offers the
opportunity to spare normal tissues and reduce toxicity.123
Personalised medicine has already been demonstrated to iden-
tify new therapeutic targets in cancer, including T-ALL, and
we strongly believe that this approach will transform the out-
look for this disease.124 We propose a combination of geno-
mics and drug profiling may enable the most appropriate
treatment to be selected. However, such an approach is not
without its difficulties, given the cost and requirement for
rapid results, especially in a disease as aggressive as T-ALL.
The paucity of validated biomarkers means there is no quick
answer for the best treatment for an individual and for the
moment such approaches are only feasibly delivered by large
research centres. Lastly, given the rarity of the disease, multi-
national collaborative trials will be required to make meaning-
ful progress in the relapsed/refractory setting.
Acknowledgements
R. P. is supported by a clinician-scientist fellowship from the
Kay Kendall Leukaemia Fund. S. R. is supported by a Clinician
Scientist Fellowship from Cancer Research UK (C67279/
A27957). N. F. was funded by Great Ormond Street Hospital
Children’s Charity and a Cancer Research UK Clinical PhD stu-
dentship. M. R. M. was funded by a Blood Cancer UK Bennett
Fellowship and a Biomedical Research Council Fellowship.
Research in the Wellcome - MRC Cambridge Stem Cell Institute
is funded by a grant from the Wellcome Trust (203151/Z/16/Z).
Author Contributions
RP, SER, NF and MM wrote the manuscript and generated
the figures. RP and MM had final responsibility to submit
for publication.
Conflict of interest
The authors declare no competing interests.
References
1. Goulden NJ, Knechtli CJ, Garland RJ, Langlands K, Hancock JP, Potter
MN, et al. Minimal residual disease analysis for the prediction of relapse
in children with standard-risk acute lymphoblastic leukaemia. Br J Hae-
matol. 1998;100(1):235–44.
2. O’Connor D, Enshaei A, Bartram J, Hancock J, Harrison CJ, Hough R,
et al. Genotype-specific minimal residual disease interpretation improves
stratification in pediatric acute lymphoblastic leukemia. J Clin Oncol.
2018;36(1):34–43.
3. Schrappe M, Valsecchi MG, Bartram CR, Schrauder A, Panzer-Grumayer
R, Moricke A, et al. Late MRD response determines relapse risk overall
and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL
2000 study. Blood. 2011;118(8):2077–84.
4. Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei
D, et al. Early T-cell precursor leukaemia: a subtype of very high-risk
acute lymphoblastic leukaemia. Lancet Oncol. 2009;10(2):147–56.
5. Conter V, Valsecchi MG, Buldini B, Parasole R, Locatelli F, Colombini
A, et al. Early T-cell precursor acute lymphoblastic leukaemia in children
treated in AIEOP centres with AIEOP-BFM protocols: a retrospective
analysis. Lancet Haematol. 2016;3(2):e80–e86.
6. Patrick K, Wade R, Goulden N, Mitchell C, Moorman AV, Rowntree C,
et al. Outcome for children and young people with Early T-cell precursor
acute lymphoblastic leukaemia treated on a contemporary protocol,
UKALL 2003. Br J Haematol. 2014;166(3):421–4.
7. Farah N, Kirkwood AA, Rahman S, Leon T, Jenkinson S, Gale RE, et al.
Prognostic impact of the absence of biallelic deletion at the TRG locus
for pediatric patients with T-cell acute lymphoblastic leukemia treated on
the Medical Research Council UK Acute Lymphoblastic Leukemia 2003
trial. Haematologica. 2018;103(7):e288–e292.
8. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding
AK, et al. In adults with standard-risk acute lymphoblastic leukemia, the
greatest benefit is achieved from a matched sibling allogeneic transplanta-
tion in first complete remission, and an autologous transplantation is less
effective than conventional consolidation/maintenance chemotherapy in
all patients: final results of the International ALL Trial (MRC UKALL
XII/ECOG E2993). Blood. 2008;111(4):1827–33.
9. Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, et al.
Treatment reduction for children and young adults with low-risk acute
lymphoblastic leukaemia defined by minimal residual disease (UKALL
2003): a randomised controlled trial. Lancet Oncol. 2013;14(3):199–209.
10. Sive JI, Buck G, Fielding A, Lazarus HM, Litzow MR, Luger S, et al. Out-
comes in older adults with acute lymphoblastic leukaemia (ALL): results
from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol.
2012;157(4):463–71.
11. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA,
et al. Improved outcome for children with acute lymphoblastic leukemia:
results of Dana-Farber Consortium Protocol 91–01. Blood. 2001;97
(5):1211–8.
12. Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hidde-
mann W, et al. Improved outcome in childhood acute lymphoblastic leu-
kemia despite reduced use of anthracyclines and cranial radiotherapy:
results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study
Group. Blood. 2000;95(11):3310–22.
13. Boiers C, Richardson SE, Laycock E, Zriwil A, Turati VA, Brown J, et al.
A human IPS model implicates embryonic B-myeloid fate restriction as
developmental susceptibility to B acute lymphoblastic leukemia-associated
ETV6-RUNX1. Dev Cell. 2018;44(3):362–77 e7.
14. De Bie J, Demeyer S, Alberti-Servera L, Geerdens E, Segers H, Broux M,
et al. Single-cell sequencing reveals the origin and the order of mutation
Review
ª 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. 13
acquisition in T-cell acute lymphoblastic leukemia. Leukemia. 2018;32
(6):1358–69.
15. Szczepanski T, van der Velden VH, Waanders E, Kuiper RP, Van Vlierberghe
P, Gruhn B, et al. Late recurrence of childhood T-cell acute lymphoblastic
leukemia frequently represents a second leukemia rather than a relapse: first
evidence for genetic predisposition. J Clin Oncol. 2011;29(12):1643–9.
16. Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G,
et al. T-cell acute lymphoblastic leukemia in adults: clinical features,
immunophenotype, cytogenetics, and outcome from the large random-
ized prospective trial (UKALL XII/ECOG 2993). Blood. 2009;114
(25):5136–45.
17. Gaynon PS, Harris RE, Altman AJ, Bostrom BC, Breneman JC, Hawks R,
et al. Bone marrow transplantation versus prolonged intensive chemotherapy
for children with acute lymphoblastic leukemia and an initial bone marrow
relapse within 12 months of the completion of primary therapy: Children’s
Oncology Group study CCG-1941. J Clin Oncol. 2006;24(19):3150–6.
18. Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz E, et al. Out-
come of patients treated for relapsed or refractory acute lymphoblastic
leukemia: a therapeutic advances in Childhood Leukemia Consortium
study. J Clin Oncol. 2010;28(4):648–54.
19. Samra B, Alotaibi AS, Short NJ, Khoury JD, Ravandi F, Garris R, et al. Out-
come of adults with relapsed/refractory T-cell acute lymphoblastic leuke-
mia or lymphoblastic lymphoma. Am J Hematol. 2020;95(9):E245–E247.
20. van den Berg H, de Groot-Kruseman HA, Damen-Korbijn CM, de Bont
ES, Schouten-van Meeteren AY, Hoogerbrugge PM. Outcome after first
relapse in children with acute lymphoblastic leukemia: a report based on
the Dutch Childhood Oncology Group (DCOG) relapse all 98 protocol.
Pediatr Blood Cancer. 2011;57(2):210–6.
21. Jenkinson S, Koo K, Mansour MR, Goulden N, Vora A, Mitchell C, et al.
Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell
acute lymphoblastic leukemia patients treated on the MRC UKALL 2003
trial. Leukemia. 2013;27(1):41–7.
22. Asnafi V, Buzyn A, Le Noir S, Baleydier F, Simon A, Beldjord K, et al.
NOTCH1/FBXW7 mutation identifies a large subgroup with favorable
outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group
for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study.
Blood. 2009;113(17):3918–24.
23. Breit S, Stanulla M, Flohr T, Schrappe M, Ludwig WD, Tolle G, et al.
Activating NOTCH1 mutations predict favorable early treatment
response and long-term outcome in childhood precursor T-cell lym-
phoblastic leukemia. Blood. 2006;108(4):1151–7.
24. Jotta PY, Ganazza MA, Silva A, Viana MB, da Silva MJ, Zambaldi LJ,
et al. Negative prognostic impact of PTEN mutation in pediatric T-cell
acute lymphoblastic leukemia. Leukemia. 2010;24(1):239–42.
25. Remke M, Pfister S, Kox C, Toedt G, Becker N, Benner A, et al. High-
resolution genomic profiling of childhood T-ALL reveals frequent copy-
number alterations affecting the TGF-beta and PI3K-AKT pathways and
deletions at 6q15-16.1 as a genomic marker for unfavorable early treat-
ment response. Blood. 2009;114(5):1053–62.
26. Trinquand A, Tanguy-Schmidt A, Ben Abdelali R, Lambert J, Beldjord K,
Lengline E, et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncoge-
netic risk classification of adult T-cell acute lymphoblastic leukemia: a
Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin
Oncol. 2013;31(34):4333–42.
27. Jenkinson S, Kirkwood AA, Goulden N, Vora A, Linch DC, Gale RE.
Impact of PTEN abnormalities on outcome in pediatric patients with T-
cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial.
Leukemia. 2016;30(1):39–47.
28. Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, et al. The
genomic landscape of pediatric and young adult T-lineage acute lym-
phoblastic leukemia. Nat Genet. 2017;49(8):1211–8.
29. Rothenburger T, McLaughlin KM, Herold T, Schneider C, Oellerich T,
Rothweiler F, et al. SAMHD1 is a key regulator of the lineage-specific
response of acute lymphoblastic leukaemias to nelarabine. Commun Biol.
2020;3(1):324.
30. Kurtzberg J, Ernst TJ, Keating MJ, Gandhi V, Hodge JP, Kisor DF, et al.
Phase I study of 506U78 administered on a consecutive 5-day schedule
in children and adults with refractory hematologic malignancies. J Clin
Oncol. 2005;23(15):3396–403.
31. Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M,
et al. Phase II study of nelarabine (compound 506U78) in children and
young adults with refractory T-cell malignancies: a report from the Chil-
dren’s Oncology Group. J Clin Oncol. 2005;23(15):3376–82.
32. DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT,
et al. Nelarabine induces complete remissions in adults with relapsed or
refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lym-
phoma: Cancer and Leukemia Group B study 19801. Blood. 2007;109
(12):5136–42.
33. Commander LA, Seif AE, Insogna IG, Rheingold SR. Salvage therapy
with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory
paediatric T-cell lymphoblastic leukaemia and lymphoma. Br J Haematol.
2010;150(3):345–51.
34. Kimberly P, Dunsmore SW, Devidas M, Wood BL, Esiashvili N, Eisen-
berg N, et al. COG AALL0434: a randomized trial testing nelarabine in
newly diagnosed T-cell malignancy. J Clin Oncol. 2018;36(15_-
suppl):10500.
35. Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z,
et al. Children’s Oncology Group AALL0434: a phase III randomized
clinical trial testing nelarabine in newly diagnosed T-cell acute lym-
phoblastic leukemia. J Clin Oncol. 2020;38(28):3282–93.
36. Lobry C, Oh P, Mansour MR, Look AT, Aifantis I. Notch signaling: switch-
ing an oncogene to a tumor suppressor. Blood. 2014;123(16):2451–9.
37. Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai
C, et al. c-Myc is an important direct target of Notch1 in T-cell acute
lymphoblastic leukaemia/lymphoma. Genes Dev. 2006;20(15):2096–109.
38. Mansour MR, Linch DC, Foroni L, Goldstone AH, Gale RE. High inci-
dence of Notch-1 mutations in adult patients with T-cell acute lym-
phoblastic leukemia. Leukemia. 2006;20(3):537–9.
39. Deangelo DJ, Stone RM, Silverman LB, Stock W, Attar EC, Fearen I,
et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients
with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other
leukemias. J Clin Oncol. 2006;24(18):6585.
40. Zheng H, Pritchard DM, Yang X, Bennett E, Liu G, Liu C, et al. KLF4
gene expression is inhibited by the notch signaling pathway that controls
goblet cell differentiation in mouse gastrointestinal tract. Am J Physiol
Gastrointest Liver Physiol. 2009;296(3):G490–G498.
41. Wei P, Walls M, Qiu M, Ding R, Denlinger RH, Wong A, et al. Evalua-
tion of selective gamma-secretase inhibitor PF-03084014 for its antitumor
efficacy and gastrointestinal safety to guide optimal clinical trial design.
Mol Cancer Ther. 2010;9(6):1618–28.
42. Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E,
et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T
cell acute lymphoblastic leukemia. Nat Med. 2009;15(1):50–8.
43. Knoechel B, Bhatt A, Pan L, Pedamallu CS, Severson E, Gutierrez A,
et al. Complete hematologic response of early T-cell progenitor acute
lymphoblastic leukemia to the c-secretase inhibitor BMS-906024: genetic
and epigenetic findings in an outlier case. Cold Spring Harb Mol Case
Stud. 2015;1(1):a000539.
44. Borthakur G, Martinelli G, Raffoux E, Chevallier P, Chromik J, Lithio A,
et al. Phase 1 study to evaluate Crenigacestat (LY3039478) in combina-
tion with dexamethasone in patients with T-cell acute lymphoblastic leu-
kemia and lymphoma. Cancer. 2020;127(3):372–80.
45. Habets RA, de Bock CE, Serneels L, Lodewijckx I, Verbeke D, Nittner D,
et al. Safe targeting of T cell acute lymphoblastic leukemia by pathology-
specific NOTCH inhibition. Sci Transl Med. 2019;11(494): eaau6246.
46. Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow
SC, et al. Direct inhibition of the NOTCH transcription factor complex.
Nature. 2009;462(7270):182–8.
47. Koyama D, Kikuchi J, Hiraoka N, Wada T, Kurosawa H, Chiba S, et al.
Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via
Review
14 ª 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
transcriptional repression of Notch1 in T-cell acute lymphoblastic leuke-
mia. Leukemia. 2014;28(6):1216–26.
48. Bertaina A, Vinti L, Strocchio L, Gaspari S, Caruso R, Algeri M, et al.
The combination of bortezomib with chemotherapy to treat relapsed/re-
fractory acute lymphoblastic leukaemia of childhood. Br J Haematol.
2017;176(4):629–36.
49. Mansour MR, Duke V, Foroni L, Patel B, Allen CG, Ancliff PJ, et al.
Notch-1 mutations are secondary events in some patients with T-cell
acute lymphoblastic leukemia. Clin Cancer Res. 2007;13(23):6964–9.
50. Knoechel B, Roderick JE, Williamson KE, Zhu J, Lohr JG, Cotton MJ,
et al. An epigenetic mechanism of resistance to targeted therapy in T cell
acute lymphoblastic leukemia. Nat Genet. 2014;46(4):364–70.
51. O’Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C, et al. FBW7 muta-
tions in leukemic cells mediate NOTCH pathway activation and resistance
to gamma-secretase inhibitors. J Exp Med. 2007;204(8):1813–24.
52. Palamarchuk A, Efanov A, Maximov V, Aqeilan RI, Croce CM, Pekarsky
Y. Akt phosphorylates Tal1 oncoprotein and inhibits its repressor activ-
ity. Cancer Res. 2005;65(11):4515–9.
53. Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y,
et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell
acute lymphoblastic leukemia. Blood. 2009;114(3):647–50.
54. Bandapalli OR, Zimmermann M, Kox C, Stanulla M, Schrappe M, Lud-
wig WD, et al. NOTCH1 activation clinically antagonizes the unfavorable
effect of PTEN inactivation in BFM-treated children with precursor T-cell
acute lymphoblastic leukemia. Haematologica. 2013;98(6):928–36.
55. Piovan E, Yu J, Tosello V, Herranz D, Ambesi-Impiombato A, Da Silva
AC, et al. Direct reversal of glucocorticoid resistance by AKT inhibition
in acute lymphoblastic leukemia. Cancer Cell. 2013;24(6):766–76.
56. Shepherd C, Banerjee L, Cheung CW, Mansour MR, Jenkinson S, Gale
RE, et al. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling
leading to an impaired cytotoxic response. Leukemia. 2013;27(3):650–60.
57. Daver N, Boumber Y, Kantarjian H, Ravandi F, Cortes J, Rytting ME,
et al. A phase I/II study of the mTOR inhibitor everolimus in combina-
tion with HyperCVAD chemotherapy in patients with relapsed/refractory
acute lymphoblastic leukemia. Clin Cancer Res. 2015;21(12):2704–14.
58. Hinton HJ, Alessi DR, Cantrell DA. The serine kinase phosphoinositide-
dependent kinase 1 (PDK1) regulates T cell development. Nat Immunol.
2004;5(5):539–45.
59. Juntilla MM, Wofford JA, Birnbaum MJ, Rathmell JC, Koretzky GA.
Akt1 and Akt2 are required for alphabeta thymocyte survival and differ-
entiation. Proc Natl Acad Sci USA. 2007;104(29):12105–10.
60. Trinquand A, Dos Santos NR, Tran Quang C, Rocchetti F, Zaniboni B,
Belhocine M, et al. Triggering the TCR developmental checkpoint acti-
vates a therapeutically targetable tumor suppressive pathway in T-cell
leukemia. Cancer Discov. 2016;6(9):972–85.
61. Chatenoud L, Ferran C, Reuter A, Legendre C, Gevaert Y, Kreis H, et al.
Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in rela-
tion to serum levels of tumor necrosis factor and interferon-gamma [cor-
rected]. N Engl J Med. 1989;320(21):1420–1.
62. Zenatti PP, Ribeiro D, Li W, Zuurbier L, Silva MC, Paganin M, et al.
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute
lymphoblastic leukemia. Nat Genet. 2011;43(10):932–9.
63. Vicente C, Schwab C, Broux M, Geerdens E, Degryse S, Demeyer S, et al.
Targeted sequencing identifies associations between IL7R-JAK mutations
and epigenetic modulators in T-cell acute lymphoblastic leukemia. Hae-
matologica. 2015;100(10):1301–10.
64. Shochat C, Tal N, Bandapalli OR, Palmi C, Ganmore I, te Kronnie G,
et al. Gain-of-function mutations in interleukin-7 receptor-alpha (IL7R)
in childhood acute lymphoblastic leukemias. J Exp Med. 2011;208
(5):901–8.
65. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, et al.
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.
Nature. 2012;481(7380):157–63.
66. Girardi T, Vicente C, Cools J, De Keersmaecker K. The genetics and
molecular biology of T-ALL. Blood. 2017;129(9):1113–23.
67. Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L, et al.
Somatically acquired JAK1 mutations in adult acute lymphoblastic leuke-
mia. J Exp Med. 2008;205(4):751–8.
68. Degryse S, De Bock CE, Cox L, Demeyer S, Gielen O, Mentens N, et al.
JAK3 mutants transform hematopoietic cells through JAK1 activation,
causing T-cell acute lymphoblastic leukemia in a mouse model. Blood.
2014;124(20):3092–100.
69. Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Sel-
vanathan A, et al. Efficacy of JAK/STAT pathway inhibition in murine
xenograft models of early T-cell precursor (ETP) acute lymphoblastic leu-
kemia. Blood. 2015;125(11):1759–67.
70. Degryse S, Cools J. JAK kinase inhibitors for the treatment of acute lym-
phoblastic leukemia. J Hematol Oncol. 2015;8:91.
71. Mansour MR, Reed C, Eisenberg AR, Tseng JC, Twizere JC, Daakour S, et al.
Targeting oncogenic Interleukein-7 receptor signaling with N-acetylcysteine in
T-cell acute lymphoblastuc leukaemia. Br J Haematol. 2015;168(2):230–8.
72. Delgado-Martin C, Meyer LK, Huang BJ, Shimano KA, Zinter MS,
Nguyen JV, et al. JAK/STAT pathway inhibition overcomes IL7-induced
glucocorticoid resistance in a subset of human T-cell acute lymphoblastic
leukemias. Leukemia. 2017;31(12):2568–76.
73. Verbeke D, Gielen O, Jacobs K, Boeckx N, De Keersmaecker K, Maertens
J, et al. Ruxolitinib synergizes with dexamethasone for the treatment of
T-cell acute lymphoblastic leukemia. Hemasphere. 2019;3(6):e310.
74. Li Y, Buijs-Gladdines JG, Cante-Barrett K, Stubbs AP, Vroegindeweij EM,
Smits WK, et al. IL-7 receptor mutations and steroid resistance in pedi-
atric T cell acute lymphoblastic leukemia: a genome sequencing study.
PLoS Medicine. 2016;13(12):e1002200.
75. Springuel L, Hornakova T, Losdyck E, Lambert F, Leroy E, Constanti-
nescu SN, et al. Cooperating JAK1 and JAK3 mutants increase resistance
to JAK inhibitors. Blood. 2014;124(26):3924–31.
76. Tvorogov D, Thomas D, Liau NPD, Dottore M, Barry EF, Lathi M, et al.
Accumulation of JAK activation loop phosphorylation is linked to type I
JAK inhibitor withdrawal syndrome in myelofibrosis. Sci Adv. 2018;4(11):
eaat3834.
77. De Smedt R, Morscio J, Reunes L, Roels J, Bardelli V, Lintermans B, et al.
Targeting cytokine and therapy induced PIM1 activation in T-cell acute
lymphoblastic leukemia and lymphoma. Blood. 2020;135(19):1685–95.
78. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, et al. Differ-
ential targeting of prosurvival Bcl-2 proteins by their BH3- only ligands
allows complementary apoptotic function. Mol Cell. 2005;17(3):393–403.
79. Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman
LB, et al. Maturation stage of T-cell acute lymphoblastic leukemia deter-
mines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199.
Cancer Discov. 2014;4(9):1074–87.
80. Anderson NM, Harrold I, Mansour MR, Sanda T, McKeown M, Nagyk-
ary N, et al. BCL2-specific inhibitor ABT-199 synergizes strongly with
cytarabine against the early immature LOUCY cell line but not more-dif-
ferentiated T-ALL cell lines. Leukemia. 2014;28(5):1145–8.
81. Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose
P, et al. Clinical experience with venetoclax combined with chemotherapy
for relapsed or refractory T-cell acute lymphoblastic leukemia. Clin Lym-
phoma Myeloma Leuk. 2020;20(4):212–8.
82. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ,
Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of
solid tumours. Nature. 2005;435(7042):677–81.
83. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL,
et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2
inhibition: results of a phase I study of navitoclax in patients with
relapsed or refractory disease. J Clin Oncol. 2012;30(5):488–96.
84. Mansour MR, He S, Li Z, Lobbardi R, Abraham BJ, Hug C, et al. JDP2:
an oncogenic bZIP transcription factor in T cell acute lymphoblastic leu-
kemia. J Exp Med. 2018;215(7):1929–45.
85. Li Z, He S, Look AT. The MCL1-specific inhibitor S63845 acts synergisti-
cally with venetoclax/ABT-199 to induce apoptosis in T-cell acute lym-
phoblastic leukemia cells. Leukemia. 2019;33(1):262–6.
Review
ª 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. 15
86. Cidado J, Boiko S, Proia T, Ferguson D, Criscione SW, San Martin M,
et al. AZD4573 is a highly selective CDK9 inhibitor that suppresses
MCL-1 and induces apoptosis in hematologic cancer cells. Clin Cancer
Res. 2020;26(4):922–34.
87. Leverson JD, Cojocari D. Hematologic tumor cell resistance to the BCL-2 inhi-
bitor venetoclax: a product of its microenvironment? Front Oncol. 2018;8:458.
88. Barber KE, Martineau M, Harewood L, Stewart M, Cameron E, Strefford
JC, et al. Amplification of the ABL gene in T-cell acute lymphoblastic
leukaemia. Leukemia. 2004;18(6):1153–6.
89. Graux C, Cools J, Melotte C, Quentmeier H, Ferrando A, Levine R, et al.
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lym-
phoblastic leukaemia. Nat Genet. 2004;36(10):1084–9.
90. Quintas-Cardama A, Tong W, Manshouri T, Vega F, Lennon PA, Cools
J, et al. Activity of tyrosine kinase inhibitors against human NUP214-
ABL1-positive T cell malignancies. Leukemia. 2008;22(6):1117–24.
91. Vanden Bempt M, Demeyer S, Broux M, De Bie J, Bornschein S, Men-
tens N, et al. Cooperative enhancer activation by TLX1 and STAT5 drives
development of NUP214-ABL1/TLX1-positive T cell acute lymphoblastic
leukemia. Cancer Cell. 2018;34(2):271–85 e7.
92. Frismantas V, Dobay MP, Rinaldi A, Tchinda J, Dunn SH, Kunz J, et al.
Ex vivo drug response profiling detects recurrent sensitivity patterns in
drug-resistant acute lymphoblastic leukemia. Blood. 2017;129(11):e26–e37.
93. Deenik W, Beverloo HB, Wattel MM, van Esser JW, Valk PJ, Cornelissen
JJ, et al. Rapid complete cytogenetic remission after upfront dasatinib
monotherapy in a patient with a NUP214-ABL1-positive T-cell acute
lymphoblastic leukemia. Leukemia. 2009;23(3):627–9.
94. Laukkanen S, Gronroos T, Polonen P, Kuusanmaki H, Mehtonen J,
Cloos J, et al. In silico and preclinical drug screening identifies dasatinib
as a targeted therapy for T-ALL. Blood Cancer J. 2017;7(9):e604.
95. Shi Y, Beckett MC, Blair HJ, Tirtakusuma R, Nakjang S, Enshaei A, et al.
Phase II-like murine trial identifies synergy between dexamethasone and
dasatinib in T-cell acute lymphoblastic leukemia. Haematologica. 2020.
https://doi.org/10.3324/haematol.2019.241026.
96. Sicinska E, Aifantis I, Le Cam L, Swat W, Borowski C, Yu Q, et al.
Requirement for cyclin D3 in lymphocyte development and T cell leuke-
mias. Cancer Cell. 2003;4(6):451–61.
97. Choi YJ, Li X, Hydbring P, Sanda T, Stefano J, Christie AL, et al. The
requirement for cyclin D function in tumor maintenance. Cancer Cell.
2012;22(4):438–51.
98. Pikman Y, Alexe G, Roti G, Conway AS, Furman A, Lee ES, et al. Syner-
gistic drug combinations with a CDK4/6 inhibitor in T-cell acute lym-
phoblastic leukemia. Clin Cancer Res. 2017;23(4):1012–24.
99. Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB,
et al. Targeting transcription regulation in cancer with a covalent CDK7
inhibitor. Nature. 2014;511(7511):616–20.
100. Mansour MR, Abraham BJ, Anders L, Berezovskaya A, Gutierrez A, Dur-
bin AD, et al. Oncogene regulation. An oncogenic super-enhancer
formed through somatic mutation of a noncoding intergenic element.
Science. 2014;346(6215):1373–7.
101. Olson CM, Jiang B, Erb MA, Liang Y, Doctor ZM, Zhang Z, et al. Phar-
macological perturbation of CDK9 using selective CDK9 inhibition or
degradation. Nat Chem Biol. 2018;14(2):163–70.
102. Burns MA, Liao ZW, Yamagata N, Pouliot GP, Stevenson KE, Neuberg
DS, et al. Hedgehog pathway mutations drive oncogenic transformation
in high-risk T-cell acute lymphoblastic leukemia. Leukemia. 2018;32
(10):2126–37.
103. Dagklis A, Demeyer S, De Bie J, Radaelli E, Pauwels D, Degryse S, et al.
Hedgehog pathway activation in T-cell acute lymphoblastic leukemia pre-
dicts response to SMO and GLI1 inhibitors. Blood. 2016;128(23):2642–54.
104. Vilas-Zornoza A, Agirre X, Abizanda G, Moreno C, Segura V, De Mar-
tino RA, et al. Preclinical activity of LBH589 alone or in combination
with chemotherapy in a xenogeneic mouse model of human acute lym-
phoblastic leukemia. Leukemia. 2012;26(7):1517–26.
105. Waibel M, Vervoort SJ, Kong IY, Heinzel S, Ramsbottom KM, Martin
BP, et al. Epigenetic targeting of Notch1-driven transcription using the
HDACi panobinostat is a potential therapy against T-cell acute lym-
phoblastic leukemia. Leukemia. 2018;32(1):237–41.
106. Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, et al.
KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selec-
tive anti-leukaemic activity in preclinical models of T-cell acute lym-
phoblastic leukaemia and acute myeloid leukaemia. Br J Haematol.
2013;161(1):117–27.
107. Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, et al.
TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic
leukemia. Cancer Discov. 2013;3(5):564–77.
108. Akahane K, Sanda T, Mansour MR, Radimerski T, DeAngelo DJ, Wein-
stock DM, et al. HSP90 inhibition leads to degradation of the TYK2
kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia.
Leukemia. 2016;30(1):219–28.
109. Wyatt KD, Bram RJ. Immunotherapy in pediatric B-cell acute lym-
phoblastic leukemia. Hum Immunol. 2019;80(6):400–8.
110. Zheng W, Medeiros LJ, Young KH, Goswami M, Powers L, Kantarjian
HH, et al. CD30 expression in acute lymphoblastic leukemia as assessed
by flow cytometry analysis. Leuk Lymphoma. 2014;55(3):624–7.
111. Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, et al.
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leuke-
mia (T-ALL). Blood. 2018;131(9):995–9.
112. Bonda A, Punatar S, Gokarn A, Mohite A, Shanmugam K, Nayak L,
et al. Daratumumab at the frontiers of post-transplant refractory T-acute
lymphoblastic leukemia-a worthwhile strategy? Bone Marrow Transplant.
2018;53(11):1487–9.
113. Ofran Y, Ringelstein-Harlev S, Slouzkey I, Zuckerman T, Yehudai-Ofir D,
Henig I, et al. Daratumumab for eradication of minimal residual disease
in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lym-
phoblastic leukemia. Leukemia. 2020;34(1):293–5.
114. Akkapeddi P, Fragoso R, Hixon JA, Ramalho AS, Oliveira ML, Carvalho T,
et al. A fully human anti-IL-7Ra antibody promotes antitumor activity
against T-cell acute lymphoblastic leukemia. Leukemia. 2019;33(9):2155–68.
115. Pinz S, Unser S, Rascle A. Signal transducer and activator of transcription
STAT5 is recruited to c-Myc super-enhancer. BMC Mol Biol. 2016;17:10.
116. Chen KH, Wada M, Firor AE, Pinz KG, Jares A, Liu H, et al. Novel anti-
CD3 chimeric antigen receptor targeting of aggressive T cell malignancies.
Oncotarget. 2016;7(35):56219–32.
117. Chen KH, Wada M, Pinz KG, Liu H, Lin KW, Jares A, et al. Preclinical
targeting of aggressive T-cell malignancies using anti-CD5 chimeric anti-
gen receptor. Leukemia. 2017;31(10):2151–60.
118. Mamonkin M, Rouce RH, Tashiro H, Brenner MK. A T-cell-directed chi-
meric antigen receptor for the selective treatment of T-cell malignancies.
Blood. 2015;126(8):983–92.
119. Sanchez-Martinez D, Baroni ML, Gutierrez-Aguera F, Roca-Ho H,
Blanch-Lombarte O, Gonzalez-Garcia S, et al. Fratricide-resistant CD1a-
specific CAR T cells for the treatment of cortical T-cell acute lymphoblas-
tic leukemia. Blood. 2019;133(21):2291–304.
120. Leong S, Inglott S, Papaleonidopoulou F, Orfinada K, Ancliff P, Bartram
J, et al. CD1a is rarely expressed in pediatric or adult relapsed/refractory
T-ALL: implications for immunotherapy. Blood Adv. 2020;4(19):4665–8.
121. Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis
TH, et al. CD7-edited T cells expressing a CD7-specific CAR for the ther-
apy of T-cell malignancies. Blood. 2017;130(3):285–96.
122. Maciocia PM, Wawrzyniecka PA, Philip B, Ricciardelli I, Akarca AU,
Onuoha SC, et al. Targeting the T cell receptor beta-chain constant region
for immunotherapy of T cell malignancies. Nat Med. 2017;23(12):1416–23.
123. Leon TE, Rapoz-D’Silva T, Bertoli C, Rahman S, Magnussen M, Philip B,
et al. EZH2-deficient T-cell acute lymphoblastic leukemia is sensitized to
CHK1 inhibition through enhanced replication stress. Cancer Discov.
2020;10(7):998–1017.
124. Wong M, Mayoh C, Lau LMS, Khuong-Quang DA, Pinese M, Kumar A,
et al. Whole genome, transcriptome and methylome profiling enhances
actionable target discovery in high-risk pediatric cancer. Nat Med.
2020;26(11):1742–53.
Review
16 ª 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
